Equity
-€879,841
Debts exceed assets in financial year 2025.
DNAVision
Lifetime
19 annual accounts with figures on one time axis, 22 filings since 2004peak €1.0m (2008)
-€3,731▼ €48,726
lowest -€2.3m (2010)
-€73,752▼ €48,771
peak €1.5m (2012)
-€879,841▼ €73,752
€907,663▲ 5.7%
peak 21.7 FTE (2010)
2 FTEunchanged
Board3 names since 2016
2 directors and 1 other
Owners4 names in the annual accounts
Documentsfilings and deeds
21-09-202652 days late
2025abbreviated format
Gross margin from €44,995 to -€3,731Loss of €73,752Cash from €47,396 to €19,451
Key points
from the 2025 annual accountsLosses
-€645,723 in seven years
Every financial year from 2019 to 2025 closed with a loss. 2020 was the heaviest.
Debts
€907,663 3,262% of the balance sheet
Suppliers 1%Taxes and wages 1%Other 98%
Staff
2 FTE from 21.7 in 2010
Between 2010 and 2025, 91% of the full-time equivalents disappeared.
Filings
22 annual accounts since 2004
Ten of the last ten came late. The 2016 accounts came latest: 221 days after the end of the period.
Position in the sector
-3162.3%
Lower solvency than 95% of companies in research and development. Sector median 46.3% · 344 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,618 companies had the same profile as DNAVision has now. Each dot stands for 17 companies, two years later.
84.5%
were still trading
10.0%
stopped another way
4.5%
went bankrupt
Another 1.0% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,618 companies, not a prediction for DNAVision. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
1 director appointed, 2 reappointments
Reappointments: and · Appointment: (managing director) · General meeting of 29-12-2021 · Gazette deed
Capital increase
Capital from €61,500 to €0, 20,000 shares cancelled · Capital from €0 to €630,000, 630 new shares · Capital from €630,000 to €61,500 · General meeting of 27-12-2018 · Gazette deed
Reappointment: (statutory auditor)
General meeting of 04-06-2015 · Gazette deed
Capital increase · Resignations & appointments
Capital from €110,000 to €0, 20,000 shares cancelled · Capital from €0 to €223,648.60, 22,365 new shares · Capital from €223,648.60 to €61,500 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DNAVision Charleroi | €27,822 | -€3,731 | -3162.3% | 2 |
| SORACH Sint-Katelijne-Waver | €41,070 | -€6,955 | 61.6% | - |
| Pharma Health Consulting & Services La Louvière | €73,329 | -€37,200 | -57.2% | - |
| DEMETER Sint-Gillis (bij-Brussel) | €53,942 | €239 | 0.3% | - |
| ARAPONICS Liège | €13,099 | -€1,525 | 95.1% | - |
| Biodiversity Inventory for Conservation Glabbeek | €27,820 | €4,776 | 99.2% | - |
| EKLYPS Brussels | €10,453 | €1,791 | 98.2% | - |
These companies have the same main activity as DNAVision: other research and development on natural sciences (NACE 72109). They are comparable in size and age: total assets between €10,500 and €73,300, founded between 2000 and 2011.
Official details
Source: KBO- Status
- Active since 13-05-2004Normal situation
- Activity
- Other research and development on natural sciencesNACE 72109and 1 other
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2025
- Establishment unit
- 2.139.181.8776041 Charleroi, since 16-09-2004
- Financial year end
- 31 December
- Peppol
- Reachable
Insights on DNAVision
DNAVision files the abbreviated format. That format states no turnover. The gross margin fell from €90,201 in 2006 to -€3,731 in 2025.
The balance sheet grew most from 2008 to 2010 through fixed assets.
In January 2022, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DNAVision
- What is the company number of DNAVision?
- The company number of DNAVision is 0865.300.475. The VAT number is the same number with BE in front: BE 0865.300.475.
- Where is DNAVision based?
- The registered office is at Avenue Georges Lemaitre 25, 6041 Charleroi.Company details
- What does DNAVision do?
- According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
- What is the legal form of DNAVision?
- DNAVision is a public limited company (NV).
- When was DNAVision founded?
- DNAVision was founded on 13-05-2004.
- Is DNAVision still active?
- Yes, DNAVision is an active enterprise in the KBO register.
- How many employees does DNAVision have?
- DNAVision had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does DNAVision fall under?
- In its 2025 annual accounts, DNAVision states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of DNAVision?
- The annual accounts for financial year 2025 state no turnover.
- Is DNAVision profitable?
- In financial year 2025, DNAVision made a loss of €73,752.
- Where can I find the annual accounts of DNAVision?
- DNAVision filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DNAVision due?
- DNAVision must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.